‘In this cohort of patients hospitalised for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomised, placebo-controlled trials of remdesivir therapy. (Funded by Gilead Sciences.)’
In this short conclusion in its introduction, the paper published by the New England Journal of Medicine, mentions specifically who funded it.
Read here (New England Journal of Medicine, April 10, 2020)
Worst ever Covid variant? Omicron
John Campbell shares his findings on Omicron. View here (Youtube, Nov 27, 2021)
-
‘We also used this investigation to quantify the impact of behaviours (i.e. mask wearing, handwashing) that were promoted to reduce the risk...
-
Last year, before the Covid-19 outbreak, ‘Google and one of the largest health-care networks in the United States are embroiled in a data-pr...
-
On September 14th 2020, the GPMB released its second report titled, A World in Disorder. In this report, the GPMB provides a harsh assessmen...